Icahn School of Medicine at Mount Sinai
New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Psoriasis
FollowWhat is new in Psoriasis research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- Active ComparatorPhase 3 · NCT06671483
- Active reference comparatorPhase 3 · NCT06878404
- adalimumabPhase 3 · NCT07836283 · NCT06100744 · NCT07138898 · NCT06640517
- ApremilastPhase 3 · NCT04908189 · NCT07337434
- bimekizumabPhase 3 · NCT07836283 · NCT06425549 · NCT06742333 · NCT06888193 · NCT07138898 · NCT06506916
- Blinded EnvudeucitinibPhase 3 · NCT06846541
- BMS-986165 TabletPhase 3 · NCT07326813
- Crisaborole 2% topical ointmentPhase 3 · NCT07892339
- CT-P55Phase 3 · NCT06630559
- D-2570Phase 3 · NCT07130604 · NCT07315061
- D-2570 TabletPhase 3 · NCT07326813 · NCT07489885
- DeucravacitinibPhase 3 · NCT07791199 · NCT07116967 · NCT04908189 · NCT06979453 · NCT06143878 · NCT04908202 · NCT06220604 · NCT04772079
- Deucravacitinib Matching PlaceboPhase 3 · NCT06143878 · NCT06220604
- Deucravacitinib tablets 6 mgPhase 3 · NCT07724366
- Deucravacitinib tablets placeboPhase 3 · NCT07724366
- Drug: placeboPhase 3 · NCT07672561
- Drug:WD-890Phase 3 · NCT07672561
- EtanerceptPhase 3 · NCT03997786 · NCT03451851 · NCT07138898
- EU-approved CosentyxPhase 3 · NCT06630559
- GolimumabPhase 3 · NCT05669833 · NCT07138898
- GuselkumabPhase 3 · NCT05669833 · NCT06663332 · NCT03451851 · NCT04882098 · NCT07138898
- HS-20137Phase 3 · NCT06844799 · NCT07879885
- IBI112Phase 3 · NCT07265284
- IcotrokinraPhase 3 · NCT06878404 · NCT06807424
- ICP-488 PlaceboPhase 3 · NCT06842199
- ICP-488 TabletsPhase 3 · NCT06842199
- IxekizumabPhase 3 · NCT06945107 · NCT07138898
- JNJ-77242113Phase 3 · NCT06095102 · NCT06143878 · NCT06220604 · NCT06934226 · NCT06295692 · NCT06095115
- JNJ-77242113 Matching PlaceboPhase 3 · NCT06143878 · NCT06220604
- Matching Placebo to JNJ-77242113Phase 3 · NCT06934226
- Matching Placebo to UstekinumabPhase 3 · NCT06934226
- NetakimabPhase 3 · NCT06640517
- Open-Label EnvudeucitinibPhase 3 · NCT06846541
- PicankibartPhase 3 · NCT07295509 · NCT06945107
- piclidenosonPhase 3 · NCT06643260
- PonesimodPhase 3 · NCT07362017
- QL2106 injectionPhase 3 · NCT07511647
- RisankizumabPhase 3 · NCT03675308 · NCT06865105 · NCT06641089 · NCT06100744 · NCT04862286 · NCT03671148 · NCT07138898
- RSS0393 ointment 0.03%Phase 3 · NCT07543224
- RSS0393 ointment placeboPhase 3 · NCT06918743 · NCT07543224
- SecukinumabPhase 3 · NCT06945107 · NCT07138898
- semaglutidePhase 3 · NCT06937060
- SHR-1314Phase 3 · NCT06833307
- SHR-1314 injectionPhase 3 · NCT06640257
- SHR0302 tablets、PlaceboPhase 3 · NCT04957550
- SonelokimabPhase 3 · NCT07223138 · NCT06641089 · NCT06641076
- SulodexidePhase 3 · NCT06982196
- SYHX1901Phase 3 · NCT06943950 · NCT06562894
- tacrolimus ointment 0.1%Phase 3 · NCT07892339
- TAK-279Phase 3 · NCT06550076
- tapinarof cream, 1%Phase 3 · NCT05172726
- TILD sub-cutaneous (SC) injectionPhase 3 · NCT04991116
- Tildrakizumab 100 mgPhase 3 · NCT06611163
- Total coumarin (TC) creamPhase 3 · NCT07426120
- TQH3906 capsulesPhase 3 · NCT07724366
- TQH3906 Capsules placeboPhase 3 · NCT07724366
- Tremfya®Phase 3 · NCT07511647
- UstekinumabPhase 3 · NCT07116967 · NCT05092269 · NCT06425549 · NCT06934226 · NCT05725876 · NCT07138898
- Vehicle creamPhase 3 · NCT07426120
- ZasocitinibPhase 3 · NCT07250802 · NCT07752108 · NCT07286058 · NCT06671483 · NCT06671496 · NCT07871721
- Betamethasone dipropionate 0.05%Phase 2/3 · NCT05981118
- CMS-D001 100mgPhase 2/3 · NCT07432854
- CMS-D001 50mgPhase 2/3 · NCT07432854
- OtezlaPhase 2/3 · NCT06863493
- SFA002Phase 2/3 · NCT06863493 · NCT05642182
- TapinarofPhase 2/3 · NCT05981118
- TildrakizumabPhase 2/3 · NCT03997786
- 5% GM-XANTHO [GM-XAN003]Phase 2 · NCT06620692
- AbataceptPhase 2 · NCT07138898
- AcupuncturePhase 2 · NCT07410793
- AnakinraPhase 2 · NCT07138898
- AzathioprinePhase 2 · NCT07138898
- BelimumabPhase 2 · NCT07138898
- Calcipotriol 0.005% ointmentPhase 2 · NCT07410793
- CanakinumabPhase 2 · NCT07138898
- CBP-0276 200mg BIDPhase 2 · NCT07204639
- CBP-0276 capsules 100mgPhase 2 · NCT07706530
- CertolizumabPhase 2 · NCT07138898
- Chinese herb creamPhase 2 · NCT07410793
- ClobetasolPhase 2 · NCT06742333
- Coal tar 1% & Salicylic acid 3 % solutionPhase 2 · NCT07841314
- COL-5671-PROPhase 2 · NCT07914231
- CyclosporinePhase 2 · NCT07138898
- DDY391Phase 2 · NCT07801495
- envudeucitinibPhase 2 · NCT05739435
- Faecal microbiota transplantationPhase 2 · NCT04924270
- FT2109 Dosing Regimen 1Phase 2 · NCT07869134
- FT2109 Dosing Regimen 2Phase 2 · NCT07869134
- HB0034Phase 2 · NCT06231381
- HS-10374 6mg tabletsPhase 2 · NCT06926582
- HS-10374-matched placebo tabletsPhase 2 · NCT06926582
- HS-20118Phase 2 · NCT07033234 · NCT06846710 · NCT07765628
- HSK44459 dose level 1Phase 2 · NCT07150988
- HSK44459 dose level 2Phase 2 · NCT07150988
- HSK47388Phase 2 · NCT07158268
- HydroxychloroquinePhase 2 · NCT07138898
- ICP-332 TabletsPhase 2 · NCT07251998
- inactivated Lactobacillus plantarumPhase 2 · NCT07194200
- InfliximabPhase 2 · NCT07138898
- JNJ-88545223Phase 2 · NCT07321873
- Lactobacillus plantarumPhase 2 · NCT07194200
- LeflunomidePhase 2 · NCT07138898
- LutikizumabPhase 2 · NCT06865105
- Marham AsfedajPhase 2 · NCT07841314
- Matching PlaceboPhase 2 · NCT07869134
- MethotrexatePhase 2 · NCT07543640 · NCT07261306 · NCT07169019 · NCT07337434 · NCT07138898
- Mundij wa Mushil Sawda (Unani Oral decoction)Phase 2 · NCT07841314
- MycophenolatePhase 2 · NCT07138898
- Oral Cannabis ExtractPhase 2 · NCT07839455
- Oral roflumilastPhase 2 · NCT07233291
- ORKA-001Phase 2 · NCT07290569 · NCT07449702
- ORKA-001 Induction DosePhase 2 · NCT07090330
- ORKA-001 Maintenance DosePhase 2 · NCT07090330
- ORKA-002Phase 2 · NCT07474792
- RituximabPhase 2 · NCT07138898
- Roflumilast 500 Mcg Oral TabletPhase 2 · NCT07543640
- RSS0393 OintmentPhase 2 · NCT07102888 · NCT06918743
- SDD formulaPhase 2 · NCT05815797
- SHR-1139Phase 2 · NCT07758075
- SHR-1139 and SHR-1139 pleaceboPhase 2 · NCT07758075
- SHR-1139 InjectionPhase 2 · NCT06875934 · NCT07078695
- SHR-1139 Injection PlaceboPhase 2 · NCT06875934
- SpesolimabPhase 2 · NCT03886246
- SPY002-072Phase 2 · NCT07148414
- SulfasalazinePhase 2 · NCT07138898
- TacrolimusPhase 2 · NCT07138898
- The SHR-1139 injectionPhase 2 · NCT07719530
- TocilizumabPhase 2 · NCT07138898
- TofacitinibPhase 2 · NCT07261306 · NCT07138898
- Tofacitinib Citrate Tablet 5 mgPhase 2 · NCT07406035
- Topical 2% TofacitinibPhase 2 · NCT07313072
- Topical cannabis creamPhase 2 · NCT07839455
- TQH3906 CapsulePhase 2 · NCT07406035
- TQH3906 Placebo CapsulePhase 2 · NCT07406035
- TulisokibartPhase 2 · NCT07486960
- UpadacitinibPhase 2 · NCT07138898
- WD-890 tabletPhase 2 · NCT06912165
- Bethametasone valerate 0,1% creamPhase 1/2 · NCT06887322
- CiplukanPhase 1/2 · NCT06887322
- CS32582 capsule（high dose）Phase 1/2 · NCT07129382
- CS32582 capsule（high dose） or matched placeboPhase 1/2 · NCT07129382
- CS32582 capsule（low dose）Phase 1/2 · NCT07129382
- CS32582 capsule（low dose） or matched placeboPhase 1/2 · NCT07129382
- CS32582 capsule（medium dose）Phase 1/2 · NCT07129382
- HSK44459 CreamPhase 1/2 · NCT07623486
- VehiclePhase 1/2 · NCT07623486
- ABBV-547Phase 1 · NCT07232004
- ABBV-547 PlaceboPhase 1 · NCT07232004
- Apremilast IRPhase 1 · NCT07908641
- Apremilast XRPhase 1 · NCT07908641
- Bimekizumab regimen 1 ivPhase 1 · NCT07290036
- Bimekizumab regimen 2 ivPhase 1 · NCT07290036
- Bimekizumab regimen 3 scPhase 1 · NCT07290036
- Biospecimen CollectionPhase 1 · NCT03816345
- CabozantinibPhase 1 · NCT03816345
- CKD-704Phase 1 · NCT07258745
- DRL_ABPhase 1 · NCT07744828
- FluoropyrimidinePhase 1 · NCT03816345
- HCXT-2001 TabletsPhase 1 · NCT07792928
- HCXT-2001 Tablets(A)Phase 1 · NCT07792928
- Hemay005Phase 1 · NCT06376474
- HL40626S placeboPhase 1 · NCT07736586
- HL40626S tabletsPhase 1 · NCT07736586
- HRS-4139 PlaceboPhase 1 · NCT07802964
- HRS-4139 TabletPhase 1 · NCT07802964
- IpilimumabPhase 1 · NCT03816345
- LPX-TI641Phase 1 · NCT06982352 · NCT06628206
- MK-8644Phase 1 · NCT07850310
- NivolumabPhase 1 · NCT03816345
- Platinum CompoundPhase 1 · NCT03816345
- Platinum DoubletPhase 1 · NCT03816345
- RSS0393 ointment；PlaceboPhase 1 · NCT06308393
- S-4321Phase 1 · NCT07455578
- SKYRIZIPhase 1 · NCT07258745
- TQH2929 InjectionPhase 1 · NCT06433531
- UA026Phase 1 · NCT07038720
- ZP9830Phase 1 · NCT07733089
- Probiotics and methotrexateEarly phase 1 · NCT07169019
- TheraCleanEarly phase 1 · NCT07050810
- TriamcinoloneEarly phase 1 · NCT04036188
Closest to patients
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)Changi General Hospital /ID# 208966 · Singapore, Singapore + 128 more hospitalsPhase 3Primary completion 2020
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) TherapyA Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) TherapyCentro Medico Privado de Reumatologia /ID# 208343 · San Miguel de Tucumán, Argentina + 237 more hospitalsPhase 3Primary completion 2020
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric ParticipantsA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric ParticipantsKirk Barber Reseach Inc. · Calgary, Canada + 31 more hospitalsPhase 3Primary completion 2023
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Review
Immunomodulatory Probiotics in Psoriasis: Effects on the Gut-Skin-Immune Crosstalk and Systemic Inflammation: Immunomodulatory Probiotics and Psoriasis Disease.
Immunomodulatory Probiotics in Psoriasis: Effects on the Gut-Skin-Immune Crosstalk and Systemic Inflammation: Immunomodulatory Probiotics and Psoriasis Disease.
Journal of nutrition and metabolism
PubMed · PMID 42973828Publication
Vitamin D status and systemic inflammatory burden as a predictor of biologic treatment response in psoriasis -A pilot study in Northern Ireland.
Vitamin D status and systemic inflammatory burden as a predictor of biologic treatment response in psoriasis -A pilot study in Northern Ireland.
Clinical and experimental dermatology
PubMed · PMID 42947505Publication
Effect of rosuvastatin as add-on to standard treatment on disease severity, inflammatory, and angiogenic biomarkers in chronic plaque psoriasis patients having cardiovascular risk: A nonrandomized, assessor blind, controlled clinical trial (RoSInA-P3 trial).
Effect of rosuvastatin as add-on to standard treatment on disease severity, inflammatory, and angiogenic biomarkers in chronic plaque psoriasis patients having cardiovascular risk: A nonrandomized, assessor blind, controlled clinical trial (RoSInA-P3 trial).
Perspectives in clinical research
PubMed · PMID 42948521
Find fellow researchers
Groups with active Psoriasis work.
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
King's College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
University of California, Los Angeles
Los Angeles, United States
Team details appear once the team leader joins.
Is this your team? Claim it
The University of Texas Southwestern Medical Center
Dallas, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Manchester
Manchester, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Yale University
New Haven, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Shanghai Skin Disease Hospital
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Charité – Universitätsmedizin Berlin
Berlin, Germany
Team details appear once the team leader joins.
Is this your team? Claim it